Hormone replacement therapy and associated risk of stroke in postmenopausal women

Archives of Internal Medicine

Volumn 162, Issue 17, 2002, Pages 1954-1960

  Lemaitre, Rozenn N ^a   Heckbert, Susan R ^a   Psaty, Bruce M ^a   Smith, Nicholas L ^a   Kaplan, Robert C ^a   Longstreth Jr , W T ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESTROGEN THERAPY; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STATISTICAL ANALYSIS; STROKE;

ADULT; AGED; CASE-CONTROL STUDIES; CEREBRAL HEMORRHAGE; CEREBROVASCULAR ACCIDENT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; INCIDENCE; MIDDLE AGED; POSTMENOPAUSE; PROGESTINS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; WASHINGTON; WOMEN'S HEALTH;

EID: 0037163479     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.162.17.1954     Document Type: Article

References (24)

1. Viscoli CM, Brass LM, Kernan WN, et al. A clinical trial of estrogen replacement therapy after ischemic stroke. N Engl J Med. 2001;345:1243-1249.
2. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Horwitz RI. Estrogen after ischemic stroke, effect of estrogen replacement on risk of recurrent stroke and death in the Women's Estrogen for Stroke Trial (WEST) [abstract]. Stroke. 2001;32: 329.
3. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998; 280:605-613.
4. Simon JA, Hsia J, Cauley JA, et al. Postmenopausal hormone therapy and risk of stroke: the Heart and Estrogen-progestin Replacement Study (HERS). Circulation. 2001;103:638-642.
5. Grodstein F, Manson JE, Colditz GA, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med. 2000;133:933-941.
6. Petitti DB, Sidney S, Quesenberry CP Jr, Bernstein A. Ischemic stroke and use of estrogen and estrogen/progestogen as hormone replacement therapy. Stroke. 1998;29:23-28.
7. Pedersen AT, Lidegaard O, Kreiner S, Ottesen B. Hormone replacement therapy and risk of non-fatal stroke. Lancet. 1997;350:1277-1283.
8. Longstreth WT, Nelson LM, Koepsell TD, van Belle G. Subarachnoid hemorrhage and hormonal factors in women: a population-based case-control study. Ann Intern Med. 1994;121:168-173.
9. Falkeborn M, Persson I, Terent A, et al. Hormone replacement therapy and the risk of stroke: follow-up of a population-based cohort in Sweden. Arch Intern Med. 1993;153:1201-1209.
10. Finucane FF, Madans JH, Bush TL, Wolf PH, Kleinman JC. Decreased risk of stroke among postmenopausal hormone users: results from a national cohort. Arch Intern Med. 1993;153:73-79.
11. Thompson SG, Meade TW, Greenberg G. The use of hormonal replacement therapy and the risk of stroke and myocardial infarction in women. J Epidemiol Community Health. 1989;43:173-178.
12. Boysen G, Nyboe J, Appleyard M, et al. Stroke incidence and risk factors for stroke in Copenhagen, Denmark. Stroke. 1988;19:1345-1353.
13. Paganini-Hill A, Ross RK, Henderson BE. Postmenopausal oestrogen treatment and stroke: a prospective study. BMJ. 1988;297:519-522.
14. Wilson PW, Garrison RJ, Castelli WP. Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50: the Framingham Study. N Engl J Med. 1985;313:1038-1043.
15. Rosenberg SH, Fausone V, Clark R. The Role of estrogens as a risk factor for stroke in postmenopausal women. West J Med. 1980;133:292-296.
16. Pfeffer RI. Estrogen use, hypertension and stroke in postmenopausal women. J Chronic Dis. 1978;31:389-398.
17. Psaty BM, Heckbert SR, Atkins D, et al. A review of of the association of estrogens and progestins with cardiovascular disease in postmenopausal women. Arch Intern Med. 1993;153:1421-1427.
18. Heckbert SR, Weiss NS, Koepsell TD, et al. Duration of estrogen replacement therapy in relation to the risk of incident myocardial infraction in poatmenopausal women. Arch Intern Med. 1997;157:1330-1
19. Lobo RA. Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. J Clin Endocrinol Metab. 1991;73:925-930.
20. Petitti DB. Coronary heart disease and estrogen replacement therapy: can compliance bias explain the results of observational studies? Ann Epidemiol. 1994; 4:115-118.
21. Matthews KA, Kuller LH, Wing RR, Meilahn EN, Plantinga P. Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol. 1996;143:971-978.
22. Barrett-Connor E. Postmenopausal estrogen and prevention bias. Ann Intern Med. 1991;115:455-456.
23. Oger E, Scarabin PY. Hormone replacement therapy in menopause and the risk of cerebrovascular accident. Ann Endocrinol (Paris). 1999;60:232-241.
24. Psaty BM, Smith NL, Lemaitre RN, et al. Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infraction in postmenopausal women. JAMA. 2001;285:906-913.